- Home
- CLDI vs MIRA Comparison
CLDI vs MIRA Comparison
Compare CLDI & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDI
- MIRA
- Stock Information
- Founded
- CLDI 2014
- MIRA 2020
- Country
- CLDI United States
- MIRA United States
- Employees
- CLDI N/A
- MIRA N/A
- Industry
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- MIRA Biotechnology: Pharmaceutical Preparations
- Sector
- CLDI Health Care
- MIRA Health Care
- Exchange
- CLDI Nasdaq
- MIRA Nasdaq
- Market Cap
- CLDI 18.1M
- MIRA 17.4M
- IPO Year
- CLDI N/A
- MIRA 2023
- Fundamental
- Price
- CLDI $0.76
- MIRA $1.19
- Analyst Decision
- CLDI Strong Buy
- MIRA Strong Buy
- Analyst Count
- CLDI 3
- MIRA 2
- Target Price
- CLDI $16.67
- MIRA $14.00
- AVG Volume (30 Days)
- CLDI 1.2M
- MIRA 403.3K
- Earning Date
- CLDI 03-14-2025
- MIRA 11-12-2024
- Dividend Yield
- CLDI N/A
- MIRA N/A
- EPS Growth
- CLDI N/A
- MIRA N/A
- EPS
- CLDI N/A
- MIRA N/A
- Revenue
- CLDI N/A
- MIRA N/A
- Revenue This Year
- CLDI N/A
- MIRA N/A
- Revenue Next Year
- CLDI N/A
- MIRA N/A
- P/E Ratio
- CLDI N/A
- MIRA N/A
- Revenue Growth
- CLDI N/A
- MIRA N/A
- 52 Week Low
- CLDI $0.69
- MIRA $0.51
- 52 Week High
- CLDI $16.80
- MIRA $5.01
- Technical
- Relative Strength Index (RSI)
- CLDI 29.25
- MIRA 47.95
- Support Level
- CLDI $0.83
- MIRA $1.15
- Resistance Level
- CLDI $0.94
- MIRA $1.26
- Average True Range (ATR)
- CLDI 0.12
- MIRA 0.10
- MACD
- CLDI -0.02
- MIRA 0.00
- Stochastic Oscillator
- CLDI 9.85
- MIRA 20.51
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.